<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780377</url>
  </required_header>
  <id_info>
    <org_study_id>080823</org_study_id>
    <nct_id>NCT00780377</nct_id>
  </id_info>
  <brief_title>Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients</brief_title>
  <acronym>P1A4D</acronym>
  <official_title>The Effects of Cardiac Innervation on Intra-coronary t-PA Release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart transplant recipients do not have nerves to their hearts. This protocol tests the&#xD;
      hypothesis that bradykinin mediated t-PA release in the coronary arteries will be reduced in&#xD;
      heart transplant recipients compared to healthy subjects.&#xD;
&#xD;
      This study will compare heart transplant recipients to healthy controls who are undergoing&#xD;
      cardiac cath for standard of care purposes (separate protocol) and compare the coronary&#xD;
      arteries to the forearm in transplant recipients (separate protocol) and healthy controls&#xD;
      (separate protocol).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to perform study due to unavailable drug, then unable to partner with cath lab&#xD;
  </why_stopped>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T-PA release in the coronary artery bed.</measure>
    <time_frame>Single Study Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>Single study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathology for arteriolar t-PA and sympathetic neurons</measure>
    <time_frame>Single Study Visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>Bradykinin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bradykinin</intervention_name>
    <description>Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.</description>
    <arm_group_label>Bradykinin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Heart transplant recipients undergoing annual cardiac catheterization who have&#xD;
             participated our protocol: Characterization of brachial arterial t-PA release,&#xD;
             vasodilator function, and vascular compliance and correlation with fibrinolytic&#xD;
             balance, oxidative stress, and inflammation measures in heart transplant recipients&#xD;
             (SCCOR Project 1, Aim 3C). (IRB # 070517)&#xD;
&#xD;
          2. 25 Subjects will have transplant vasculopathy and 25 subjects will be free of&#xD;
             transplant vasculopathy, as documented in previous angiograms.&#xD;
&#xD;
          3. Otherwise healthy&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. PVC &lt; 30&#xD;
&#xD;
          2. Hypertensive subjects on ACE inhibitors&#xD;
&#xD;
          3. Pregnant or nursing mothers&#xD;
&#xD;
          4. Diabetic with HbA1C &gt; 7.5 or stigmata of end organ damage (neuropathy, retinopathy,&#xD;
             nephropathy, cardiomyopathy)&#xD;
&#xD;
          5. Cholesterol &gt; 30 mg/dL above NCEP accepted level based on cardiac risk.&#xD;
&#xD;
          6. Triglycerides &gt; 200&#xD;
&#xD;
          7. Previously diagnosed obstructive coronary artery disease&#xD;
&#xD;
          8. Renal insufficiency (Creatinine ≥ 1.5 mg/dl)&#xD;
&#xD;
          9. History of cerebrovascular disease&#xD;
&#xD;
         10. Any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc)&#xD;
&#xD;
         11. Uncontrolled Stage 2 Hypertension (160/100 mmHg), or end organ damage due to&#xD;
             hypertension (left ventricular hypertrophy, atrial fibrillation, hematuria, renal&#xD;
             insufficiency, prior cerebrovascular disease).&#xD;
&#xD;
         12. Angiotensin converting enzyme inhibitor use&#xD;
&#xD;
         13. Coagulopathy (INR ≥ 1.5, PTT ≥ 150% of control)&#xD;
&#xD;
         14. Peripheral Vascular Disease&#xD;
&#xD;
         15. Other chronic medical illnesses at the discretion of the investigators&#xD;
&#xD;
        Healthy controls are being enrolled in SCCOR Project 1, Aims 3A and 3B (IRB# 030473 and&#xD;
        061160) and will not be participating under this IRB number.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A S AS Muldowney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>James Muldowney</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Heart Transplant</keyword>
  <keyword>Fibrinolysis</keyword>
  <keyword>Resting conditions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradykinin</mesh_term>
    <mesh_term>Kininogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

